RxDoctor Payments Data

Thomas King, MD

Cardiovascular Disease · Saint Louis, MONPI 1639162530

Payments from drug & device makers

$6,633in general payments, 2019–2025

Across 394 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Johnson & Johnson$823
  • Astellas Pharma US Inc$470
  • Pfizer$470
  • Amgen$449
  • Merck$357
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$6,52898%
  • Education$1052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,633 in reported general payments places this provider in the 65th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$160,168
Medicare patients
823
Services billed
5,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban313$297,000
EntrestoSacubitril/Valsartan110$128,712
XareltoRivaroxaban62$76,540
Repatha SureclickEvolocumab35$32,186
JardianceEmpagliflozin27$19,234
FarxigaDapagliflozin Propanediol22$19,211
CorlanorIvabradine Hcl17$12,260
BrilintaTicagrelor14$7,841
Metoprolol Succinate290$3,522
ClopidogrelClopidogrel Bisulfate217$2,705
Amiodarone Hcl144$2,612
Atorvastatin Calcium252$2,388
Ranolazine ErRanolazine17$1,874
Carvedilol246$1,716
Dilt-XrDiltiazem Hcl51$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$470$297,000313 claims
NovartisEntresto$1,921$128,712110 claims
Johnson & JohnsonXarelto$823$76,54062 claims
AstraZenecaFarxiga, Brilinta$325$27,05236 claims
Boehringer IngelheimJardiance$197$19,23427 claims
AmgenCorlanor$449$12,26017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →